Hedera Dx raises EUR 15 million to expand access to precision cancer care

Hedera Dx has secured EUR 15 million to expand hospital-based cancer diagnostics, making precision oncology more accessible to patients worldwide.

Hedera Dx, a Lausanne-based company specializing in precision oncology, has secured EUR 15 million in Series A financing to broaden global access to advanced cancer care. The funding will support the commercial expansion of its blood-based cancer testing solutions and enhance its real-world data infrastructure.

Founded in 2021 and headquartered at Biopôle in Lausanne, Hedera Dx is addressing a persistent challenge in oncology: limited patient access to targeted therapies due to centralized testing models. Outside the United States, where centralized diagnostics dominate, many healthcare systems require testing to occur within hospital laboratories. To meet this need, Hedera Dx has developed a cost-efficient and scalable liquid biopsy solution that enables hospitals to perform molecular diagnostics on-site.

Already deployed in 11 European countries, the company’s liquid biopsy platform combines high-quality molecular profiling with an AI-driven engine that generates patient-centric insights. These insights not only support physicians in making personalized treatment decisions but also help biopharma partners accelerate the development of next-generation oncology treatments.

The Series A round was led by Vsquared Ventures, with new investor Tesi joining existing backers Helsana HealthInvest, Eyrir Venture Management, Inventure, and Top Harvest. The capital will help Hedera Dx scale its solution to more healthcare systems worldwide and further its goal of making precision oncology a standard offering.

Hedera Dx’s leadership team brings deep experience from companies like Blueprint Genetics, Roche, and Molecular Health. The company positions itself at the intersection of diagnostics and real-world data, with a long-term vision to become a global platform for cancer care innovation.

With this new investment, Hedera Dx is accelerating its mission to remove structural barriers in oncology, enabling broader patient access to life-saving, targeted treatments.